The Report Guru

Introduction : Cancer, a formidable global health challenge, requires early detection and effective monitoring for improved patient outcomes. Traditional tissue biopsies have been the gold standard, but they are invasive, costly, and often provide limited information. Enter liquid biopsy, a non-invasive and innovative approach that is revolutionizing cancer detection and monitoring. In this blog post, we will delve into the world of liquid biopsy, exploring its benefits, applications, and market insights based on a report by MarketsandMarkets. Market Insights and Future Prospects: The liquid biopsy market is witnessing significant growth and is projected to reach USD 10.0 billion by 2027 from USD 4.3 billion in 2022, at a CAGR of 18.3%. Rise in incidences and prevalence of various cancer types, improvements in liquid biopsy technology, rise in demand of non-invasive procedures, and promising government initiatives improve the market growth. Factors contributing to this g...

The global liquid biopsy market is projected to reach USD 10.0 billion by 2027 from USD 4.3 billion in 2022, at a CAGR of 18.3% during the forecast period. Growth in the liquid biopsy market is mainly driven by factors such as the rising incidence and prevalence of cancer, awareness initiatives undertaken by global health organizations, and the increasing preference for noninvasive treatment procedures. However, the lower sensitivity of certain liquid biopsies might act as a restraining factor to the growth of this market. The key players in the liquid biopsy market are F. Hoffmann-La Roche Ltd. (Switzerland), Myriad Genetics, Inc. (US), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific, Inc. (US), Guardant Health, Inc. (US), MDxHealth SA (Belgium), Exact Sciences Corporation (US), Illumina Inc. (US), Sysmex Inostics (US), Bio-Rad Laboratories, Inc. (US), Biocept, Inc. (US), NeoGenomics, Inc. (US), ANGLE plc (UK), Menarini-Silicon Biosystems (Italy), Vortex Biosciences...

Liquid biopsy is a non-invasive diagnostic technique that involves the detection of cancer biomarkers in the blood or other bodily fluids. It is a rapidly growing field, with the potential to revolutionize cancer diagnosis and treatment. In this blog, we will explore the liquid biopsy industry, its market size, and trends, as well as the factors driving the growth of the industry. Market Size and Trends The global liquid biopsy market size was valued at USD 4.3 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 18.3% from 2022 to 2027. The increasing prevalence of cancer, the growing adoption of liquid biopsy for early cancer detection, and the development of advanced liquid biopsy technologies are the key factors driving the growth of the liquid biopsy industry. Types of Liquid Biopsy There are two main types of liquid biopsy: circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA). CTCs are cells that have detached from the prim...

Introduction to Liquid Biopsy Liquid biopsy is a non-invasive procedure which uses a sample of a patient's blood to detect cancer cells. This can be used to monitor the progression of a disease and to detect genetic changes that may be associated with the disease. It is a relatively new technique which is being used to identify early markers of cancer and to provide more information about the cancer cells than traditional biopsies. Liquid biopsy can also be used to identify drug-resistant mutations in cancer cells, which can help guide drug treatment decisions. With this technology, it is possible to detect cancer cells at an early stage and to monitor the cancer's progression without having to perform a traditional biopsy. Overview of Liquid Biopsy Industry Liquid biopsy is a non-invasive test to detect cancer in the body using a sample of blood. It has revolutionized the detection of cancer and is used to detect tumor-associated genetic mutations, tumor-specific ...

The increasing preference for noninvasive treatment procedures, the rising incidence and prevalence of cancer, and awareness initiatives undertaken by global health organizations are the major factors driving the liquid biopsy market growth. According to research report the global liquid biopsy market size is projected to reach $5.8 billion by 2026 from $2.5 billion in 2021, at a CAGR of 18.1% during the forecast period.In 2020, the cancer application segment accounted for the largest share of the liquid biopsy industry.   The market is segmented by Product (Assay Kits, Instruments, Service), Circulating Biomarkers (CTC, ctDNA), Technology (NGS, PCR), Application (Cancer (Lung, Breast, Prostate), Non-Cancer), End User (Reference Lab, Hospitals) Geography Download PDF Brochure : https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=13966350 Based on product service, the liquid biopsy market is segmented into assay kits, instruments, and services. In 2020, the assay k...

Liquid Biopsy Market  is projected to reach USD 5.8 billion by 2026 from USD 2.5 billion in 2021, at a CAGR of 18.1% according to a new report by MarketsandMarkets™. The rising incidence and prevalence of cancer and the increasing preference for noninvasive treatment procedures are among the major factors propelling the growth of this market. Emerging economies such as China, Japan, and India are providing lucrative opportunities for the players operating in the liquid biopsy market. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=13966350 Browse in-depth TOC on "liquid biopsy market” 152 – Tables 50 – Figures 231 – Pages The reference laboratories segment accounted for the largest share of the liquid biopsy, by end user segment, in 2020 Based on end users, the liquid biopsy market has been segmented into reference laboratories, hospitals and physician laboratories, academic research centers, and other end users. In 2020, the reference ...

The increasing preference for noninvasive treatment procedures, the rising incidence and prevalence of cancer, and awareness initiatives undertaken by global health organizations are the major factors driving the liquid biopsy market growth. According to research report the global liquid biopsy market size is projected to reach $5.8 billion by 2026 from $2.5 billion in 2021, at a CAGR of 18.1% during the forecast period. In 2020, the cancer application segment accounted for the largest share of the liquid biopsy market. Based on application, the liquid biopsy market is segmented into cancer and non-cancer applications. The large share of this segment can be mainly attributed to factors such as the increasing prevalence of cancer and the growing number of research studies on liquid biopsy for cancer applications. Download PDF Brochure : https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=13966350 In 2020, the assay kits segment accounted for the largest share of the l...

Market growth due to rising incidence and prevalence of cancer and the increasing preference for noninvasive treatment procedures these factors propelling the growth of this market. Emerging economies such as China, Japan, and India are providing lucrative opportunities for the players operating in the Liquid Biopsy Market . According to the new market research report  global liquid biopsy market size is projected to reach USD 5.8 billion by 2026 from USD 2.5 billion in 2021, at a CAGR of 18.1%. Based on product & service, the market is segmented into assay kits, instruments, and services. The assay kits segment accounted for the largest share of the liquid biopsy market in 2020. The standard purchase requirement of assay kits makes them a recurrent cost which is a key factor boosting the market growth of this segment. Download PDF Brochure : https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=13966350 The liquid biopsy market is segmented into circulating tumor c...

According to a new market research report Liquid Biopsy Market by Cancer Type (Lung, Breast, Colorectal, Prostate), Circulating Biomarkers (Circulating Tumor Cells, Circulating Tumor DNA, Cell-Free DNA), Product (Instruments, Assay Kits), End User (Reference Laboratory) - Global Forecast to 2022, published by MarketsandMarkets™, the market is expected to reach USD 2,047.9 Million by 2022 from an estimated USD 715.7 Million in 2017, at a CAGR of 23.4%. The key factors driving the growth of this market include increasing prevalence of cancer, increasing preference for noninvasive procedures, initiatives undertaken by government and global health organizations, technological advancement to augment market revenues, rising emphasis on personalized medicine, and availability of funding for liquid biopsy R&D. Browse 133 Market Data Tables and 44 Figures spread through 204 Pages and in-depth TOC on "Liquid Biopsy Market" Download PDF Brochure: https://www.marketsa...

According to the market research report Liquid Biopsy Market is expected to reach $2,047.9 Million by 2022 from an estimated $715.7 Million in 2017, at a CAGR of 23.4%. Some of the key factors driving the growth of this market include increasing preference for noninvasive procedures, increasing prevalence of cancer and availability of funding for liquid biopsy R&D. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=13966350 The key players in the global liquid biopsy market are QIAGEN N.V. (Netherlands), Roche Diagnostics (US), Bio-Rad Laboratories Inc. (US), Myriad Genetics, Inc. (US), Menarini Silicon Biosystems (Italy), Genomic Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Biocept, Inc. (US), Trovagene, Inc. (US), Guardant Health, Inc. (US), RainDance Technologies, Inc. (US), and MDx Health SA (US). By clinical application, the therapy selection segment is expected to account fors the largest market share in 201...

According to the market research report Liquid Biopsy Market is expected to reach $2,047.9 Million by 2022 from an estimated $715.7 Million in 2017, at a CAGR of 23.4%. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=13966350 Some of the key factors driving the growth of this market include increasing preference for noninvasive procedures, increasing prevalence of cancer and availability of funding for liquid biopsy R&D. The key players in the global liquid biopsy market are QIAGEN N.V. (Netherlands), Roche Diagnostics (US), Bio-Rad Laboratories Inc. (US), Myriad Genetics, Inc. (US), Menarini Silicon Biosystems (Italy), Genomic Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Biocept, Inc. (US), Trovagene, Inc. (US), Guardant Health, Inc. (US), RainDance Technologies, Inc. (US), and MDx Health SA (US). By clinical application, the therapy selection segment is expected to account fors the largest market share in 201...

 According to the market research report Liquid Biopsy Market is expected to reach $2,047.9 Million by 2022 from an estimated $715.7 Million in 2017, at a CAGR of 23.4%. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=13966350 Some of the key factors driving the growth of this market include increasing preference for noninvasive procedures, increasing prevalence of cancer and availability of funding for liquid biopsy R&D. The key players in the global liquid biopsy market are QIAGEN N.V. (Netherlands), Roche Diagnostics (US), Bio-Rad Laboratories Inc. (US), Myriad Genetics, Inc. (US), Menarini Silicon Biosystems (Italy), Genomic Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Biocept, Inc. (US), Trovagene, Inc. (US), Guardant Health, Inc. (US), RainDance Technologies, Inc. (US), and MDx Health SA (US). By clinical application, the therapy selection segment is expected to account fors the largest market share i...

According to the new market research Liquid Biopsy Market is expected to reach $2,047.9 Million by 2022 from an estimated $715.7 Million in 2017, at a CAGR of 23.4%. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=13966350 The key factors driving the growth of this market include increasing prevalence of cancer, initiatives undertaken by government and global health organizations, increasing preference for non-invasive procedures, technological advancement to augment market revenues, rising emphasis on personalized medicine, and availability of funding for liquid biopsy R&D. The liquid biopsy market is a consolidated market with a large number of companies offering liquid biopsy instruments and accessories. In 2016, QIAGEN N.V. (Netherlands), Roche Diagnostics (US), and Illumina, Inc. (US) dominated the liquid biopsy market. The key players in the global liquid biopsy market are QIAGEN N.V. (Netherlands), Roche Diagnostics (US), Bio-Rad La...

Liquid Biopsy Market Market Growth Factors: The key factors driving the growth of this market include increasing prevalence of cancer, increasing preference for non-invasive procedures, initiatives undertaken by government and global health organizations, technological advancement to augment market revenues, rising emphasis on personalized medicine, and availability of funding for liquid biopsy R&D. Market Size: According to the new market research Liquid Biopsy Market is expected to reach $2,047.9 Million by 2022 from an estimated $715.7 Million in 2017, at a CAGR of 23.4%. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=13966350 Market Segments: Based on product and service, the liquid biopsy market is segmented into assay kits, instruments, and services. Among these, the assay kits segment is expected to be the fastest-growing segment in the product and services market during the forecast period. Factors such as the increasi...